# siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery siRNA 设计和 GalNAc 增强的肝靶向递送

Mei Lu, Mengjie Zhang, Bo Hu and Yuanyu Huang 

## Abstract 摘要

Small interfering RNA (siRNA) is a clinically approved therapeutic modality, which has attracted widespread attention not only from basic research but also from pharmaceutical industry. As siRNA can theoretically modulate any disease-related gene’s expression, plenty of siRNA therapeutic pipelines have been established by tens of biotechnology companies. The drug performance of siRNA heavily depends on the sequence, the chemical modification, and the delivery of siRNA. Here, we describe the rational design protocol of siRNA, and provide some modification patterns that can enhance siRNA’s stability and reduce its off-target effect. Also, the delivery method based on *N*-acetylgalactosamine (GalNAc)-siRNA conjugate that is widely employed to develop therapeutic regimens for liver-related diseases is also recapitulated.

<span style=color:blue>小干扰RNA（siRNA）是一种已经获得临床批准的治疗方式，不仅在基础研究中广受关注，也吸引了制药行业的广泛兴趣。由于siRNA理论上能够调控任何与疾病相关的基因表达，许多生物技术公司已经建立了大量的siRNA治疗管线。siRNA的药物性能在很大程度上取决于其序列、化学修饰以及递送方式。本文描述了siRNA的合理设计方案，并提供了一些能够增强siRNA稳定性和减少脱靶效应的修饰模式。此外，本文还概述了基于*N*-乙酰半乳糖胺（GalNAc）-siRNA偶联物的递送方法，这种方法被广泛用于开发治疗肝脏相关疾病的方案。</span>

## 1 Introduction 介绍

RNA interference (RNAi) based on small interfering RNA (siRNA) is not only widely used to regulate gene expression in basic research areas but also represents a clinically approved therapeutic platform that can be investigated for treating diverse life-threaten diseases, such as metabolic disorders, genetic or orphan diseases, infectious diseases, and cancers. Mature siRNA can be generated by both chemical synthesis and processing from short hairpin RNA (shRNA) or long double-stranded RNA with Dicer (Fig. 1). Once the siRNA duplex is introduced into the cytoplasm of cells, it will be incorporated into the RNA-induced silencing complex (RISC). Then the sense (passenger) strand of siRNA is released from RISC, and the antisense (guide) strand of siRNA will recognize the target complementary mRNA in a complete match manner. Finally, the target mRNA will be cleaved by Argonaut protein in RISC. The cleaved mRNA fragments are further degraded by cellular 5′ and 3′ exonucleases (Fig. .1). In contrast to the recognition mode of “complete match with target mRNA,” microRNA (miRNA), another representative member of RNAi family, modulates gene’s expression in a “partial match” or “seed match” manner. In which way, only the seed region of the miRNA (position of 2–8 from 5′ end) needs to match with the targeted gene. Nucleic acid therapeutics based on both siRNA and miRNA are investigated for treating diseases currently, although siRNA is more potent and popular for drug development. siRNA and miRNA are usually considered to be generated exogenously and endogenously, respectively. Hence, the sequences of siRNA are artificially designed, while the sequences of miRNA are selected from naturally existing miRNA library. Actually, the activity of siRNA molecules is highly dependent on the sequence since not all double-stranded RNA molecules that completely matched with target mRNA can trigger efficient gene silence. Many factors contribute to the overall activity of siRNA, such as G and C content, the stability of the 3′ terminus of the sense strand (it will determine which strand of the duplex will be loaded into RISC), the nucleotide (base) type of the 5′ and 3′ end of antisense strand. Taken together, rational design of siRNA is essentially required.

<span style=color:blue>基于小干扰 RNA (siRNA) 的 RNA 干扰 (RNAi) 技术不仅在基础研究领域广泛用于调控基因表达，而且还是一种经过临床验证的治疗平台，可用于治疗多种危及生命的疾病，例如代谢紊乱、遗传病或罕见病、传染病和癌症。成熟的siRNA可以通过化学合成以及由短发夹RNA（shRNA）或长双链RNA经Dicer处理生成（见图1）。siRNA 双链进入细胞质后，会被整合到 RNA 诱导沉默复合物 (RISC) 中。然后，siRNA的正义（乘客）链将从RISC中释放，而反义（引导）链将以完全匹配的方式识别目标互补mRNA。最终，目标mRNA将被RISC中的Argonaut蛋白切割，并被细胞的5′和3′外切酶进一步降解（见图1）。与“完全匹配目标mRNA”的识别模式不同，微小RNA（miRNA）是RNAi家族的另一代表成员，它通过“部分匹配”或“种子匹配”的方式调控基因表达。在这种方式中，仅需要miRNA的种子区域（位于5′末端的2-8位）与目标基因匹配。尽管siRNA在药物开发中更有效且更受欢迎，但目前基于siRNA和miRNA的核酸疗法都在用于治疗疾病的研究中。通常认为，siRNA和miRNA分别是外源性和内源性生成的。因此，siRNA的序列可以是人工设计的，而miRNA的序列是从自然存在的miRNA库中选择的。实际上，siRNA分子的活性高度依赖于其序列，因为并非所有完全匹配目标mRNA的双链RNA分子都能引发有效的基因沉默。许多因素影响siRNA的整体活性，例如G和C的含量、正义链3′末端的稳定性（这将决定双链中的哪条链被加载到RISC中）、以及反义链5′和3′末端的核苷酸（碱基）类型。综上所述，siRNA的合理设计是必不可少的。</span>

![485053_1_En_6_Fig1_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_6_Fig1_HTML.png)

<span style=font-family:kaiti;text-align:center>**Fig. 1** Working mechanism of siRNA. Synthetic siRNA or Dicer-processed siRNA is incorporated into RNA-induced silencing complex (RISC). The sense (passenger) strand is removed and the antisense (guide) strand will recognize the full complementary mRNA. Then Argonaut protein in RISC cleaves the target mRNA, and the protein translation is blocked.<span style=color:blue>siRNA 的工作机制。合成的 siRNA 或 Dicer 处理的 siRNA 被整合到 RNA 诱导沉默复合物 (RISC) 中。正义链 (乘客链) 被移除，反义链 (引导链) 将识别完整的互补 mRNA。然后 RISC 中的 Argonaut 蛋白切割目标 mRNA，并阻断蛋白质翻译</span></span>

In addition, the issues of metabolic stability, specificity, and off-target effect are the key determinants of drug performances in vivo. Both the sequence and chemical modification may contribute to these issues. For instance, siRNA with UA/UA and/or CA/UG paring in the sequence is more sensitive to RNase attacking, and modifications in these bases can enhance its resistance to enzyme’s degradation. All the mismatch type (e.g., A-G, A-C, A-A, and G-U, G-A, G-G, etc.), mismatch position (from 5′-end to 3′-end of siRNA, and on coding region or untranslated region of mRNA), and mismatch number (one or two or more mismatches) could affect the activity and specificity of siRNA. Chemical modification may also change the strand selection of RISC, thus contributing to enhancing the specificity of siRNA. The off-target effect of siRNA may occur through several different mechanisms, including: (1) passenger strand of siRNA binds to undesired target mRNA; (2) the seed regions of passenger or guide strand of siRNA recognize certain mRNA sequence, especially at the 3′-untranslated region (UTR) region, and silence gene’s expression in a “miRNA-like” way; (3) passenger or guide strand of siRNA bind to toll-like receptors (TLRs, e.g., TLR3), stimulate immune response, and affect downstream gene’s expression. Various chemical modification strategies have been investigated to reduce the off-target effect of siRNA. For example, 2′-*O*-methyl (OMe) modification at position 14 of the siRNA passenger strand can be used to abolish the activity of the passenger strand. Unlocked nucleic acid (UNA) and glycol nucleic acid (GNA) at position 7 of the siRNA guide strand dramatically reduced the “miRNA-like” off-target effect. Actually, recognition of toll-like receptors and stimulation of immune response directly caused the termination of Phase III study of Bevasiranib, the first-ever clinically investigated siRNA therapeutic, in 2009. Disturbance of the expression of undesired target genes resulted from the seed regions of both strands of siRNA may also trigger significant hepatotoxicity in animals . Therefore, rational chemical modifications are extremely important for drug development.

<span style=color:blue>此外，代谢稳定性、特异性和脱靶效应是体内药物性能的关键因素。siRNA的序列和化学修饰都可能影响这些因素。例如，含有UA/UA和/或CA/UG配对的siRNA序列更易受到RNase攻击，对这些碱基进行修饰可以提高其抗酶降解能力。错配类型（如A-G、A-C、A-A和G-U、G-A、G-G等）、错配位置（从siRNA的5′端到3′端，或在mRNA的编码区或非翻译区）以及错配数量（一个、两个或更多）都可能影响siRNA的活性和特异性。化学修饰还可能改变RISC的链选择，从而提高siRNA的特异性。siRNA的脱靶效应可能通过几种不同的机制发生，包括：（1）siRNA的乘客链结合到不希望的目标mRNA；（2）siRNA的乘客链或引导链的种子区域识别某些mRNA序列，尤其是在3′-非翻译区（UTR）区域，以类似miRNA的方式沉默基因表达；（3）siRNA的乘客链或引导链结合到Toll样受体（TLRs，如TLR3），刺激免疫反应，并影响下游基因表达。为了减少siRNA的脱靶效应，已经研究了各种化学修饰策略。例如，siRNA乘客链第14位的2′-O-甲基（OMe）修饰可以消除乘客链的活性。siRNA引导链第7位的解锁核酸（UNA）和乙二醇核酸（GNA）显著减少了类似miRNA的脱靶效应。实际上，Toll样受体的识别和免疫反应的刺激直接导致了2009年首个临床研究的siRNA疗法Bevasiranib的三期研究终止。siRNA双链种子区域对不希望的目标基因表达的干扰也可能在动物中引发显著的肝毒性。因此，合理的化学修饰对药物开发极为重要。</span>

Moreover, insufficient delivery of siRNA to the targeted tissue and cell significantly hampered siRNA therapeutic development for a long period. Because the cell membrane is primarily made up of zwitterionic and negatively charged phospholipids, and shows a negative potential (−40 to −80 mV) across the cell membrane, it is difficult for the negatively charged siRNA to cross cell membrane by itself. Hence, various delivery platforms, including chemically synthesized materials (such as liposomes, polymers, dendrimers, and inorganic nanoparticles), biological agents (such as peptides, antibodies, aptamers , CpG, 3-Way Junction, and exosomes), and physical approaches (such as electroporation, microneedle poking, hydrodynamic injection, and microfluidic extrusion), have been developed to deliver siRNA to desired tissues and cells (Fig. 2). Among them, *N*-Acetylgalactosamine (GalNAc)-siRNA conjugate exhibits excellent hepatocyte-targeted delivery efficiency and safety profile in vivo (Fig. 2d, e, g) . GalNAc can be recognized by asialoglycoprotein receptor (ASGPR) that is conserved across species and highly expressed by hepatocytes, and can mediate clathrin-involved endocytosis. It takes only 15 min for GalNAc from binding to ASGPR to being internalized into the cell and re-displaying on cell surface. After thoroughly exploring the effects of valence of oligosaccharides, distance among the targeting moieties, and size of the particle on the binding performance, researchers reached a consensus that triantennary GalNAc with a mutual distance of ~20 Å exhibits the highest affinity with ASGPR. By conjugating three GalNAc moieties to the siRNA with proper linker chemistry, siRNA can be efficiently delivered to hepatocytes via subcutaneous injection. Benefiting from the enhanced stabilization modification, GalNAc-siRNA conjugate can remain in the circulation system and cytoplasm for more than 100 days, thus permitting a long-term gene silencing and therapeutic effect in human beings. The reduction profile could be well maintained for more than 6 months or even 1 year, after a single dose of GalNAc-siRNA, as demonstrated by abundant clinical data.

<span style=color:blue>此外，siRNA在目标组织和细胞中的递送不足长期以来严重阻碍了siRNA疗法的发展。由于细胞膜主要由带双电荷和负电荷的磷脂组成，并且细胞膜显示负电位（-40到-80 mV），导致带负电荷的siRNA难以自行穿过细胞膜。因此，开发了多种递送平台，包括化学合成材料（如脂质体、聚合物、树枝状分子和无机纳米颗粒）、生物制剂（如肽、抗体、适配体、CpG、三向结点和外泌体）以及物理方法（如电穿孔、微针刺、液体动力注射和微流体挤出）来将siRNA递送到目标组织和细胞（图2）。其中，N-乙酰半乳糖胺（GalNAc）-siRNA偶联物在体内表现出优异的肝细胞靶向递送效率和安全性（图2d、e、g）。GalNAc可以被去唾液酸糖蛋白受体（ASGPR）识别，这种受体在肝细胞表面高表达，并且在不同物种间保守。GalNAc 与 ASGPR 结合后，可以介导网格蛋白 (clathrin) 依赖性内吞作用，将 siRNA 送入肝细胞。从 GalNAc 与 ASGPR 结合到被细胞内化并重新返回到细胞表面仅需 15 分钟。经过深入研究寡糖的价数、靶向基团之间的距离和颗粒大小对结合性能的影响，研究人员一致认为，三天线GalNAc相距约20 Å时与ASGPR具有最高亲和力。通过合适的化学连接子将三个GalNAc基团偶联到siRNA上，可以通过皮下注射有效地将siRNA递送到肝细胞。得益于增强的稳定性修饰，GalNAc-siRNA偶联物可以在循环系统和细胞质中停留超过100天，从而在人体内实现长期的基因沉默和治疗效果。丰富的临床数据表明，单剂量的GalNAc-siRNA的减少效果可以保持超过6个月甚至1年。</span>



**Fig. 2**

![485053_1_En_6_Fig2_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_6_Fig2_HTML.png)<span style=font-family:kaiti;text-align:center>Schemes and structures of representative siRNA delivery platforms. Schemes of (**a**) lipid nanoparticles, (**b**) DPC2.0™ or EX-1™, (**c**) TRiM™, (**d**) GalNAc-siRNA conjugates, (**e**) GalXC™ and (**f**) LODER™, respectively. (**g**) Chemical structures of the key component(s) of the discussed delivery platforms, including Dlin-DMA, Dlin-MC3-DMA, C12-200, cKK-E12, MLP-based DPC2.0, PLGA-based LODER, and GalNAc-siRNA conjugates. *DPC*, Dynamic PolyConjugates; *TRiM*, Targeted RNAi Molecule; *LODER*, LOcal Drug EluteR; *PLGA*, poly(lactic-co-glycolic) acid; *MLP*, membrane-lytic peptide, with the amino sequence NH-LIGAILKVLATGLPTLISWIKNKRKQ-COOH; *CDM*, carboxylated dimethyl maleic acid; *PEG*, polyethylene glycol; *NAG*, *N*-acetylgalactosamine (GalNAc)<span style=color:blue>代表性 siRNA 递送平台的方案和结构。分别为 (**a**) 脂质纳米粒子、(**b**) DPC2.0™ 或 EX-1™、(**c**) TRiM™、(**d**) GalNAc-siRNA 结合物、(**e**) GalXC™ 和 (**f**) LODER™ 的方案。 (**g**) 所讨论的递送平台的关键组件的化学结构，包括 Dlin-DMA、Dlin-MC3-DMA、C12-200、cKK-E12、基于 MLP 的 DPC2.0、基于 PLGA 的 LODER 和 GalNAc-siRNA 结合物。*DPC*，动态多聚结合物；*TRiM*，靶向 RNAi 分子；*LODER*，局部药物洗脱剂；*PLGA*，聚（乳酸-乙醇酸）共聚物； *MLP*，膜溶解肽，氨基酸序列为 NH-LIGAILKVLATGLPTLISWIKNKRKQ-COOH；*CDM*，羧化二甲基马来酸；*PEG*，聚乙二醇；*NAG*，*N*-乙酰半乳糖胺 (GalNAc)</span></span>

In this chapter, we will introduce the siRNA design method with online-accessible tools, discuss chemical modification strategies, and recapitulate the experimental design process of GalNAc-mediated liver-targeted siRNA delivery. It may provide a brief roadmap for researches from both academic institute and pharmacy industry.

<span style=color:blue>本章将介绍siRNA设计方法及在线工具，讨论化学修饰策略，并重述GalNAc介导的肝靶向siRNA递送的实验设计过程。它可为学术机构和制药行业的研究提供简要的路线图。</span>

## 2 Materials 材料

### 2.1 Software, Database, and Equipment 软件、数据库与设备

1. DNAMAN 8, and/or online alignment tool (http://molbiol-tools.ca/Alignments.htm). 

   <span style=color:blue>DNAMAN 8，和/或在线比对工具（http://molbiol-tools.ca/Alignments.htm)</span>

2. “LALIGN,” use following website: https://embnet.vital-it.ch/software/LALIGN_form.html (*see* **Note** **1**). 

   <span style=color:blue>LALIGN”，使用以下网站：https://embnet.vital-it.ch/software/LALIGN_form.html（*见* **注释** **1**）</span>

3. Online siRNA design tools (*see* **Note** **2**). 

   <span style=color:blue>在线 siRNA 设计工具（*见* **注释** **2**）</span>

4. NCBI database, including the sub-databases of “Gene” (https://www.ncbi.nlm.nih.gov/gene/) and “Nucleotide” (https://www.ncbi.nlm.nih.gov/nucleotide/). 

   <span style=color:blue>NCBI 数据库，包括“基因”子数据库（https://www.ncbi.nlm.nih.gov/gene/）和“核苷酸”子数据库（https://www.ncbi.nlm.nih.gov/nucleotide/）</span>

5. NCBI tool of Blastn: https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome 

   <span style=color:blue>Blastn 的 NCBI 工具：https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome</span>

6. Extended Nucleic Acid Sequence Massager: https://www.cmbn.no/tonjum/seqMassager-saf.htm 

   <span style=color:blue>扩展核酸序列“按摩器”：https://www.cmbn.no/tonjum/seqMassager-saf.htm</span>

7. A personal computer with Microsoft office and access to the World Wide Web. 

   <span style=color:blue>一台装有 Microsoft Office 并能访问万维网的个人电脑</span>

8. Microvolume Spectrophotometers. 

   <span style=color:blue>微量分光光度计</span>

9. Real-time PCR machine. 

   <span style=color:blue>实时荧光定量PCR仪</span>

10. Multi-Detection Microplate Reader. 

    <span style=color:blue>多重检测酶标仪</span>

11. Luminex 100 system.

    <span style=color:blue>Luminex 100 系统</span>

### 2.2 Reagents 试剂

1. siRNA, including GalNAc-siRNA conjugate. 

   <span style=color:blue>siRNA，包括GalNAc-siRNA偶联物。</span>

2. Lipofectamine 2000 (Thermo Fisher Scientific, USA). 

3. DMEM medium: Dulbecco’s Modified Eagle’s Medium (DMEM) without supplement. 

   <span style=color:blue>DMEM培养基：杜氏改良伊格尔培养基（DMEM），无添加。</span>

4. HEK293A medium: DMEM medium supplemented with 1% penicillin-streptomycin, and 10% fetal bovine serum. 

   <span style=color:blue>HEK293A培养基：添加1%青霉素-链霉素和10%胎牛血清的DMEM培养基。</span>

5. Perfusion solution 1: Hank’s Balanced Salt Solution (HBSS) supplemented with 0.5 mM EDTA, pH = 8. 

   <span style=color:blue>灌注液1：添加0.5 mM EDTA的Hank平衡盐溶液（HBSS），pH=8。</span>

6. Perfusion solution 2: DMEM medium supplemented with 0.8 mg/mL collagenase type I. 

   <span style=color:blue>灌注液2：添加0.8 mg/mL I型胶原酶的DMEM培养基</span>

7. Primary mouse hepatocyte medium: DMEM medium supplemented with 10% fetal bovine serum, but without adding antibiotics. 

   <span style=color:blue>小鼠原代肝细胞培养基：添加10%胎牛血清的DMEM培养基，但不添加抗生素</span>

8. Opti-MEM medium (Thermo Fisher Scientific, USA) with no supplement. 

   <span style=color:blue>Opti-MEM培养基（美国赛默飞世尔科技公司），无添加</span>

9. Trypsin. 

   <span style=color:blue>胰蛋白酶</span>

10. Trizol. 

11. Cell culture plates. 

    <span style=color:blue>细胞培养板</span>

12. Serological pipettes. 

    <span style=color:blue>血清移液器</span>

13. Reverse transcription kit. 

    <span style=color:blue>逆转录试剂盒</span>

14. Real-time PCR kit (UltraSYBR Mixture). 

    <span style=color:blue> </span><span style=color:blue>实时 PCR 试剂盒（UltraSYBR Mixture）</span>

15. RNAlater. 

16. Dual luciferase reporter system: the primary plasmid vectors of siQuant and psiCheck. 

    <span style=color:blue>双荧光素酶报告系统：siQuant 和 psiCheck 的初级质粒载体</span>

17. Luciferase detection kit. 

    <span style=color:blue>荧光素酶检测试剂盒</span>

18. Plasmid isolation kit. 

    <span style=color:blue>质粒分离试剂盒</span>

19. Anesthetic: 4% Chloral hydrate solution (w/v). 

    <span style=color:blue>麻醉剂：4% 水合氯醛溶液（w/v）</span>

### 2.3 Cells and Animals 细胞与动物

1. HEK293A originally derived from human embryonic kidney cells . Culture HEK293A cells in HEK293A medium. 

   <span style=color:blue>HEK293A 最初来源于人胚胎肾细胞。在 HEK293A 培养基中培养 HEK293A 细胞。</span>

2. Male C57BL/6 mice (age 6–8 weeks). 

   <span style=color:blue>雄性 C57BL/6 小鼠（6-8 周龄）</span>

## 3 Methods 方法

RNAi therapeutic companies may establish their own siRNA design algorithm and develop their confidential software. Here we just introduce how to design siRNAs with online accessible tools. Firstly, design siRNAs with online tools that are accessible for public (Table 1). Then evaluate the activity, stability, and off-target effect in vitro. After narrowing down the number of siRNA candidates, apply chemical modifications to the siRNAs, and evaluate the performance of siRNA again. Then conjugate three or four (typically three) GalNAc moieties to the siRNA with proper linker chemistry. Finally, inject the GalNAc-siRNA conjugate into the mice subcutaneously and assess the in vivo gene silence and toxicity.

<span style=color:blue>RNAi治疗公司可能会建立自己的siRNA设计算法并开发保密软件。在这里，我们仅介绍如何使用在线可访问工具设计siRNA。首先，使用对公众开放的在线工具设计siRNA（表1）。然后在体外评估其活性、稳定性和脱靶效应。在缩小siRNA候选范围后，对siRNA进行化学修饰，并再次评估其性能。然后使用适当的连接化学将三个或四个（通常为三个）GalNAc基团偶联到siRNA上。最后，将GalNAc-siRNA偶联物皮下注射到小鼠体内，并评估其体内基因沉默效果和毒性。</span>

**Table 1** Selected online siRNA design tools and their features <span style=color:blue>可选择的在线siRNA设计工具及其功能</span>

<div class="c-table-scroll-wrapper__content c-table-scroll-wrapper__fade c-table-scroll-wrapper__fade--transparent" data-component-scroll-wrapper=""><table class="data last-table"><thead class="c-article-table-head"><tr><th class="u-text-left "><p>Tool</p></th><th class="u-text-left "><p>Developer (owner)</p></th><th class="u-text-left "><p>Website</p></th><th class="u-text-left "><p>Rules or features</p></th></tr></thead><tbody><tr><td class="u-text-left "><p>siDESIGN Center</p></td><td class="u-text-left "><p>Dharmacon/Horizon Discovery</p></td><td class="u-text-left "><p>https://horizondiscovery.com/products/tools/siDESIGN-Center</p></td><td class="u-text-left "><p>(a)&emsp;30–52% G/C content</p><p>(b)&emsp;At least 3 “A/U” bases at positions 15–19 (sense strand)</p><p>(c)&emsp;Absence of internal repeats (Tm of potential internal hairpin is &lt;20&nbsp;°C)</p><p>(d)&emsp;An “A” base at position 19 (sense strand)</p><p>(e)&emsp;An “A” base at position 3 (sense strand)</p><p>(f)&emsp;A “U” base at position 10 (sense strand)</p><p>(g)&emsp;A base other than “G” or “C” at 19 (sense strand)</p><p>(h)&emsp;A base other than “G” at position 13 (sense strand)</p></td></tr><tr><td class="u-text-left "><p>siDirect 2.0</p></td><td class="u-text-left "><p>University of Tokyo</p></td><td class="u-text-left "><p>http://sidirect2.rnai.jp/</p></td><td class="u-text-left "><p>(a)&emsp;A or U at position 19 (guide strand, from 5′ to 3′)</p><p>(b)&emsp;Four to seven A/Us in nucleotide positions 1–7 (A/U&nbsp;≥&nbsp;57%)</p><p>(c)&emsp;G/C at position 19</p><p>(d)&emsp;No long GC stretch (≤9 GC)</p><p>(e)&emsp;Low thermodynamic stability in the duplex formed between the siRNA 7-nt seed region and the target mRNA (Tm&nbsp;≤&nbsp;21.5&nbsp;°C)</p></td></tr><tr><td class="u-text-left "><p>Block-iT RNAi Designer</p></td><td class="u-text-left "><p>Invitrogen/Thermo Fisher Scientific</p></td><td class="u-text-left "><p>https://rnaidesigner.invitrogen.com/rnaiexpress/setOption.do?designOption=sirna</p></td><td class="u-text-left "><p>Unspecified algorithm; partially based on Tuschl’s rules and patterns</p></td></tr><tr><td class="u-text-left "><p>DSIR</p></td><td class="u-text-left "><p>Ecole des Mines de Paris</p></td><td class="u-text-left "><p>http://www.bioinfo.ensmp.fr/dsir/</p></td><td class="u-text-left "><p>Based on linear models over two sets of features: (1) the nucleotides present at each position; (2) the global content of the siRNA in short motifs. Short asymmetric motifs contain as much relevant information for potency prediction as the nucleotide preferences for particular positions</p></td></tr><tr><td class="u-text-left "><p>GenScript siRNA Target Finder</p></td><td class="u-text-left "><p>GenScript</p></td><td class="u-text-left "><p>https://www.genscript.com/tools/sirna-target-finder</p></td><td class="u-text-left "><p>Following factors are taken into account:</p><p>(a)&emsp;Internal stability of siRNA duplex</p><p>(b)&emsp;Specificity of the siRNA target sequence</p><p>(c)&emsp;Internal secondary structure of the sense and anti-sense strands</p><p>(d)&emsp;Sequence complexity</p><p>(e)&emsp;Single nucleotide polymorphism</p><p>(f)&emsp;Other adjustable algorithm parameters include GC content, asmmetrey of double strands of the siRNA duplex, sequence region, etc.; other adjustable off target filter include study organism, study organ, size of seed region and functional alignment</p></td></tr><tr><td class="u-text-left "><p>RNAi Design Tool</p></td><td class="u-text-left "><p>IDT</p></td><td class="u-text-left "><p>https://sg.idtdna.com/site/order/designtool/index/DSIRNA_CUSTOM</p></td><td class="u-text-left "><p>Support vector machine (SVM)-based selection</p></td></tr><tr><td class="u-text-left "><p>siDRM</p></td><td class="u-text-left "><p>University of Minnesota</p></td><td class="u-text-left "><p>http://c1.accurascience.com/siDRM/index.php</p></td><td class="u-text-left "><p>High sensitivity rule sets and fast rule sets based on disjunctive rule merging (DRM) analysis. Innate immune responses, cell toxic effects and off-target activities are taken into consideration</p></td></tr><tr><td class="u-text-left "><p>siRNA Selection Server</p></td><td class="u-text-left "><p>Whitehead Institute</p></td><td class="u-text-left "><p>http://jura.wi.mit.edu/bioc/siRNAext/</p></td><td class="u-text-left "><p>Functionality prediction limited to Tuschl or user-defined pattern-based selection; incorporates design rules that published before 2004</p></td></tr><tr><td class="u-text-left "><p>OptiRNA</p></td><td class="u-text-left "><p>University of Nebraska-Lincoln</p></td><td class="u-text-left "><p>http://optirna.unl.edu/</p></td><td class="u-text-left "><p>Support vector machine (SVM)-based selection; mRNA secondary structure is taken into account; does NOT run BLAST searches</p></td></tr></tbody></table></div>

*Ref.(s)* reference(s), *NA* not available

### 3.1 Primary Mouse Hepatocyte Isolation 小鼠原代肝细胞分离

Isolate primary mouse hepatocytes from C57BL/6 mice according to the protocol reported previously and described as following.

<span style=color:blue>根据之前报道的方案从 C57BL/6 小鼠中分离小鼠原代肝细胞，如下所述。</span>

1. Anesthetize the animals by intraperitoneally injecting a saline solution containing 80 mg/kg Ketamine and 5 mg/kg Xylazine. 

   <span style=color:blue>通过腹膜内注射含有 80 mg/kg 氯胺酮和 5 mg/kg 赛拉嗪的盐水溶液对动物进行麻醉。</span>

2. Prepare the animal for surgery (clean/sanitize). 

   <span style=color:blue>准备动物进行手术（清洁/消毒）</span>

3. Immobilize the animal with tape. Dissect the abdominal cavity, move the gastric system to the right, and expose liver. 

   <span style=color:blue>用胶带固定动物。解剖腹腔，将胃系统移到右侧，暴露肝脏</span>

4. To start perfusion, insert the catheter into the vena cava through the right atrium. The flow rate should be 5 mL/min. 

   <span style=color:blue>将导管通过右心房插入下腔静脉，流速设为 5 mL/min，开始灌注。</span>

5. Create back pressure by blocking the visceral vena cava with a finger when the blood is drained out. Perfuse for 5–7 min.

   <span style=color:blue>当血液流尽时，用手指阻塞内脏下腔静脉以产生背压。灌注 5-7 分钟。</span>

6. Position a lamp a few inches above the animal to maintain the cavity temperature of 37 °C throughout the procedure. 

   <span style=color:blue>将灯放置在动物上方几英寸处，以在整个过程中保持腔内温度为 37 °C</span>

7. Switch the tubing from perfusion solution 1 to perfusion solution 2, and continue perfusion for 7–8 min (flow rate 5 mL/min).

   <span style=color:blue>将管从灌注溶液 1 切换到灌注溶液 2，并继续灌注 7-8 分钟（流速 5 mL/min）</span>

8. Collect the liver into perfusion solution 2, and cut the liver sac to release the hepatocytes.

   <span style=color:blue>将肝脏收集到灌注溶液 2 中，切开肝囊以释放肝细胞</span>


9. Add DMEM medium and pass the liver suspension through a cell strainer. 

   <span style=color:blue>加入 DMEM 培养基，并通过细胞滤器过滤肝细胞悬液</span>

10. Spin cells at 800 rpm for 5 min. Wash the pellet twice with DMEM medium. 

    <span style=color:blue>将细胞以 800 rpm 离心 5 分钟。用 DMEM 培养基清洗沉淀物两次</span>

11. Count cells with a hemocytometer and culture in primary mouse hepatocyte medium. 

    <span style=color:blue>使用血细胞计数板计数细胞，并用原代小鼠肝细胞培养基进行培养</span>


### 3.2 siRNA Design and Screening siRNA的设计与筛选

#### 3.2.1 mRNA (cDNA) Selection mRNA（cDNA）选择

1. Identify the target gene that we intend to silence. 

   <span style=color:blue>确定需要沉默的靶基因</span>

2. Determine the accession number(s) of the mRNA sequence(s) of the target gene, and/or download the mRNA (cDNA) sequence(s) in a FASTA format. 

   <span style=color:blue>确定靶基因 mRNA 序列的登录号，和/或以 FASTA 格式下载 mRNA (cDNA) 序列。</span>

3. Analyze mRNA (cDNA) sequence(s) and determine the sequence(s) that will be used to design siRNA according to the workflow shown in Fig. 3(*see* **Note** **3**). 

   <span style=color:blue>根据图 3 所示的工作流程分析 mRNA (cDNA) 序列并确定将用于设计 siRNA 的序列（*参见* **注释** **3**）。</span>


![485053_1_En_6_Fig3_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_6_Fig3_HTML.png)

**Fig. 3** Workflow of mRNA (cDNA) sequence selection <span style=color:blue>mRNA(cDNA)序列选择流程图</span>

#### 3.2.2 Generation of siRNA Sequence List 生成siRNA序列列表

1. Submit mRNA (cDNA) sequence of interest, or the accession number of the target gene, to the online siRNA design tools. The available online tools and related information are summarized in Tables 1 and 2. 

   <span style=color:blue>将目标基因的 mRNA (cDNA) 序列或基因序列编号提交到在线 siRNA 设计工具。常用的在线工具及其相关信息总结于表格 1 和 2 中</span>

2. Establish a series of siRNA design algorithms by analyzing hundreds and thousands of siRNAs. The silencing activity, selectivity, off-target effect, as well as the mRNA secondary structure, alternative splicing, or the motif sequences may potentially trigger immune response when they were taken into accounts. One or more design tools can be used when submitting mRNA (cDNA) sequence. 

   <span style=color:blue>（siRNA 设计工具）通过分析数百乃至数千条 siRNA 序列，建立一系列设计算法。沉默活性、选择性、脱靶效应，以及mRNA二级结构、可变剪接或可能引发免疫反应的基序序列都需要考虑在内。在提交 mRNA (cDNA) 序列时，可以选择一个或多个设计工具进行 siRNA 设计。</span>

3. siRNA list exported by the selected tool is automatically generated. Typically, 3–5 siRNA candidates that rank on the top of the list can be selected for further evaluation. High-ranking siRNAs means their scores are relatively high because the features of these sequences match better with the algorithm than other sequences (*see* **Notes** **4** and **5**). 

   <span style=color:blue>选定的在线工具会自动生成 siRNA 列表。一般会选择列表中排名靠前的 3-5 个 siRNA 序列进行后续实验验证。排名越靠前的 siRNA 得分通常越高，这表示这些序列的特征更符合设计算法的要求 (参见**注释** **4** 和 **5**)。</span>

4. Synthesize the siRNAs without chemical modification (*see* **Note** **6**). 

   <span style=color:blue>合成没有化学修饰的siRNA（参见**注释** **6**)</span>

**Table 2** Representative siRNA designing algorithms and their attributes

| Authors            | Tool            | Position (5′–3′, cDNA form) | 1    | 3    | 6    | 10   | 11   | 13    | 16   | 19   |
| :----------------- | :-------------- | :-------------------------- | :--- | :--- | :--- | :--- | :--- | :---- | :--- | :--- |
| Reynolds et al.    | siDESIGN Center | Preferred                   |      | A    |      | T    |      | A/C/T |      | A/T  |
| Ui-Tei et al.      | siDirect 2.0    | Preferred                   | G/C  |      |      |      |      |       |      | A/T  |
|                    |                 | Unpreferred                 | A/T  |      |      |      |      |       |      | G/C  |
| Amarzguioui et al. | NA              | Preferred                   | G/C  |      | A    |      |      | T     | C    | A/T  |
|                    |                 | Unpreferred                 | T    |      |      | T    |      |       |      | G    |
| Jagla et al.       | NA              | Preferred                   | G/C  |      |      | A/T  |      |       |      | A/T  |
| Hsieh et al.       | NA              | Preferred                   |      |      |      |      | C/G  | A     | G    | T    |
| Unpreferred        |                 |                             | C    |      | A/T  |      |      | G     |      |      |

*Ref*. reference, *NA* not available

#### 3.2.3 Activity Evaluation 活性评估

1. Evaluate the activities of siRNA candidates via either luciferase reporter system or reverser transcription quantitative PCR (RT-qPCR), or both (*see* **Note** **7**). 

   <span style=color:blue>通过荧光素酶报告系统或逆转录定量PCR（RT-qPCR）或两者结合评估siRNA候选物的活性（参见**注释** **7**）</span>

2. For luciferase reporter assay, insert the target sequences into the siQuant reporter vector according to standard molecular clone procedures (*see* **Note** **8**). 

   <span style=color:blue>对于荧光素酶报告实验，根据标准分子克隆程序将目标序列插入siQuant报告载体中（参见**注释** **8**）</span>

3. Transfect siRNAs into the Hek293A cells with Lipofectamine 2000 at various transfection concentrations (at least three concentrations, e.g., 10 nM, 1 nM, and 0.1 nM; or more than seven concentration gradients that enable building a concentration-activity curve and calculating the IC<sub>50</sub>), together with the reporter vectors (*see* **Note** **9**). 

   <span style=color:blue>将siRNA与Lipofectamine 2000一起转染入Hek293A细胞，并使用不同的转染浓度（至少三个浓度，例如10 nM、1 nM和0.1 nM；或超过七个浓度梯度以构建浓度-活性曲线并计算IC<sub>50</sub>），同时转染报告载体（参见**注释** **9**）</span>

4. 24 h later, harvest the cells and prepare cell lysates. Then, transfer 10μL cell lysates to the reader plate, and add the substrates of Firefly and Renilla luciferases into the samples sequentially. Detect the luminance signal with Multi-Detection Microplate Reader. 

   <span style=color:blue>24小时后，收获细胞并制备细胞裂解液。然后，将10μL细胞裂解液转移到读板中，依次向样品中添加萤火虫和海肾荧光素酶的底物。使用多检测微孔板读板仪检测发光信号</span>

5. For RT-qPCR assay, transfect the siRNAs into the cells that endogenously express the target gene at desired concentrations (typically no less than three concentrations, e.g., 100, 20, and 5 nM). 

   <span style=color:blue>对于RT-qPCR检测，将siRNA以期望的浓度（通常不少于三个浓度，例如100、20和5 nM）转染到内源性表达目标基因的细胞中。</span>

6. 24 or 48 h later, harvest the cells and extract the total RNA according to the standard procedures. Verify the quality of total RNA by separating in agarose gel and analyzing with Microvolume Spectrophotometers. 

   <span style=color:blue>24或48小时后，收获细胞并按照标准程序提取总RNA。通过琼脂糖凝胶电泳分离和微量体积分光光度计分析验证总RNA的质量。</span>

7. Prepare the cDNA with 1μg total RNA in a 20μL standard reaction solution, then use 80μL ddH<sub>2</sub>O to dilute the cDNA solution. 

   <span style=color:blue>使用1μg总RNA在20μL标准反应液中制备cDNA，然后使用80μL ddH<sub>2</sub>O稀释cDNA溶液。</span>

8. Perform the quantitative PCR with a 20μL reaction solution containing 5μL of cDNA template by using a PCR machine . 

   <span style=color:blue>使用含有5μL cDNA模板的20μL反应液进行定量PCR反应，使用PCR仪进行检测。</span>

9. Finally, calculate the inhibition efficiency with the Ct values by normalizing to the control group (e.g., mock without transfection siRNA, or scrambled siRNA-treated sample, or untreated sample) (*see* **Notes** **10-12**). 

   <span style=color:blue>最后，通过标准化对照组（例如未转染siRNA的空白对照组、处理过无序列siRNA的样品或未处理样品）的Ct值计算抑制效率（参见**注释** **10-12**）</span>


#### 3.2.4 Off-Target Effect Evaluation 脱靶效应评估

1. Assess the off-target effect of siRNAs with either psiCheck reporter system or RNA-seq technology. 

   <span style=color:blue>siRNA 的脱靶效应可以使用 psiCheck 报告系统或 RNA-seq 技术进行评估</span>

2. For psiCheck-based off-target effect evaluation, transfect siRNAs into Hek293A at concentration gradients ranged from 50 nM, 0.5 nM, 0.25 nM, 0.125 nM, 0.0625 nM, 0.0313 nM, 0.0156 nM, 0.0078 nM, 0.0039 nM, 0.002 nM, 0.001 nM to 0.0005 nM. 

   <span style=color:blue>对于基于 psiCheck 的脱靶效应评估，将 siRNA 转染到 Hek293A 细胞中，浓度梯度范围为 50 nM、0.5 nM、0.25 nM、0.125 nM、0.0625 nM、0.0313 nM、0.0156 nM、0.0078 nM、0.0039 nM、0.002 nM、0.001 nM 和 0.0005 nM</span>

3. Record the enzymes’ activities of Renilla and Firefly luciferases with Multi-Detection Microplate Reader. Then generate the concentration-activity curves and calculate the IC<sub>50</sub>s with GraphPad Prism software. 

   <span style=color:blue>使用多功能检测微孔板读板仪记录海肾和萤火虫萤光素酶的酶活性。然后利用 GraphPad Prism 软件生成浓度-活性曲线并计算 IC<sub>50 </sub>值</span>

4. With this reporter-based assay, the off-target effects resulted from complete-match of the passenger strand with the target or from seed-match of either the guide or the passenger strand with the target can be quickly determined. 

   <span style=color:blue>这种基于报告系统的检测可以快速确定由乘客链完全匹配靶序列或引导链/乘客链种子序列匹配靶序列引起的脱靶效应。</span>

5. Alternatively, apply high throughput RNA-seq, a newly developed technology to evaluate the expression inhibition of numerous endogenously expressing genes both in vitro and in vivo (Fig. 7b). 

   <span style=color:blue>RNA-seq 是一种新开发的技术，可以用于评估体外和体内大量内源表达基因的表达抑制 (图 7b)</span>

6. In this circumstance, prepare total RNA with high quality from either cultured cells (cell lines or primary cells) or tissue samples. Perform the RNA-seq usually by Contract Research Organization (CRO). Analyze the data by ourselves (if feasible) or the researchers of CRO. Finally, figure out the expression levels of all on-target genes and those off-target transcripts.

   <span style=color:blue> 首先，需从培养的细胞 (细胞系或原代细胞) 或组织样本中提取高质量的总 RNA。通常由专业合同研究组织 (CRO) 进行 RNA-seq 检测。数据分析可以由研究者自己完成 (如果可行) 或由 CRO 的研究人员完成。最后，分析所有靶基因和脱靶转录物的表达水平</span>

7. Assess the off-target effect resulted from the immune response, such as activation of the TLRs pathway, by measuring the cytokine levels and the expression of relevant genes (e.g., TNF-α, IL-6, IL-12, IFN-γ, IFIT genes). 

   <span style=color:blue>通过测量细胞因子水平和相关基因 (例如 TNF-α、IL-6、IL-12、IFN-γ、IFIT 基因) 的表达来评估由免疫反应引起的脱靶效应，例如 TLRs 通路激活</span>


### 3.3 siRNA Chemical Modification siRNA 化学修饰

1. It is well known that chemical modification of siRNA is extremely essential for siRNA therapeutic development because it can significantly enhance siRNA’s capability of resistance to enzymes’ attacking, improve siRNA’s specificity, and reduce potential off-target effects. Sophisticated modification strategies have been proposed and investigated for both siRNA with canonical structure or Dicer-substrate siRNA (DsiRNA) (Fig. 4). Chemical structures of the representative modification building blocks are shown in Fig. 5. 

   <span style=color:blue>siRNA的化学修饰对于其治疗药物的开发非常重要，因为这种修饰可以显著提高siRNA抵抗酶攻击的能力，提高其特异性，并减少潜在的离靶效应。对于具有常规结构的siRNA或Dicer底物siRNA（DsiRNA），已经提出并研究了多种复杂的修饰策略（见图4）。常用修饰结构式如图 5 所示。</span>

2. Select siRNA modification design from Fig. 4. Alternatively, test additional designs based on these patterns or other novel designs. 

   <span style=color:blue>从图4中选择siRNA的修饰设计。此外，还可以基于这些模式或其他新设计进行额外的测试。</span>

3. Among these designs, 2′-fluoro (2′-F), 2′-*O*-methoxy (2′-OMe), DNA, phosphorothioate, and inverted base (idT/A) are primarily employed to enhance siRNA’s stability , while unlocked nucleic acid (UNA) and glycol nucleic acid (GNA) positioned at 7 of the antisense strand are used to reduce the off-target effect mediated by seed region (Fig. 7a). 

   <span style=color:blue>在这些设计中，2′-氟（2′-F）、2′-*O*-甲氧基（2′-OMe）、DNA、硫代磷酸酯和倒置碱基（idT/A）主要用于增强siRNA的稳定性，而解锁核苷酸（UNA）和乙二醇核苷酸（GNA）定位于反义链的第7位，用于减少由种子区介导的离靶效应（见图7a）</span>


![485053_1_En_6_Fig4_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_6_Fig4_HTML.png)

**Fig. 4** Examples of siRNA chemical modification design. GalNAc, *N*-acetylgalactosamine, can be placed at 3′-end or 5′-end of the sense strand. For DsiRNA, they can be positioned at the unpaired G-A-A-A nucleotides. Abbreviations: *2*′*-F* 2′-fluoro, *2′-OMe* 2′-methoxy, *UNA* unlocked nucleic acid, *GNA* glycol nucleic acid, *SS* sense strand, *AS* antisense strand

![485053_1_En_6_Fig5_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_6_Fig5_HTML.png)

**Fig. 5** Chemical structures of siRNA modification building blocks. R=H or OH, for RNA or DNA, respectively

### 3.4 In Vivo Delivery of GalNAc-siRNA Conjugate GalNAc-siRNA偶联物的体内递送

1. As aforementioned, GalNAc-siRNA conjugate constitutes one of the most powerful and successful delivery platforms for liver-targeted transportation of siRNA. Therefore, dozens of siRNA therapeutic pipelines have been established, aiming to treat diverse diseases including hyperlipidemia, hepatitis B, amyloidosis, etc. 

   <span style=color:blue>如前所述，GalNAc-siRNA偶联物是目前最强大且最成功的siRNA肝脏靶向运输平台之一。因此，已经建立了几十条siRNA治疗管线，旨在治疗包括高脂血症、乙型肝炎、淀粉样变性等多种疾病。</span>

2. Display GalNAc moieties at the 3′-end or 5′-end of the sense strand of siRNA. Alnylam Pharmaceuticals, Silence Therapeutics, Arbutus Biopharma, etc., conjugate trivalent GalNAc at the 3′-end of siRNA sense strand, while Arrowhead Pharmaceuticals demonstrate there is no significant difference between 3′-conjugation and 5′-conjugation. Dicerna Pharmaceuticals position tetravalent GalNAc at the unpaired nucleotides of the DsiRNA structure. A challenging task for this field is to develop proprietary linker structures. A series of different linkers have been designed, and some of them can deliver oligonucleotides to hepatocytes efficiently. The linker chemistry developed by Alnylam is shown in Fig. 2g. 

   <span style=color:blue>GalNAc 配体可以修饰在 siRNA 双链乘客链的 3' 端或 5' 端。Alnylam Pharmaceuticals、Silence Therapeutics、Arbutus Biopharma等公司在siRNA正义链的3′末端偶联三价GalNAc，而Arrowhead Pharmaceuticals则表明3′-端偶联和5′-端偶联之间没有显著差异。Dicerna Pharmaceuticals则将四价GalNAc定位于DsiRNA结构中未配对的核苷酸。该领域的一个挑战性任务是开发专有的连接子结构。已经设计了一系列不同的连接子，其中一些可以有效地将寡核苷酸递送到肝细胞。Alnylam开发的连接子化学结构如图2g所示。</span>


### 3.5 In Vivo Activity of GalNAc-siRNA Conjugate GalNAc-siRNA偶联物的体内活性

1. Subcutaneously (SC) administer GalNAc-siRNA conjugate into the mice (male C57BL/6, 6–8 weeks, weighing 18–22 g) at 0.5–10 mg/kg (*see* **Note** **13**). 

   <span style=color:blue>将GalNAc-siRNA偶联物以皮下注射（SC）的方式注射到小鼠体内（雄性C57BL/6，6–8周龄，体重18–22克），剂量为0.5–10 mg/kg（参见**注释** **13**）。</span>

2. Sacrifice animals by cervical dislocation, harvest the liver tissues 3 days or 1 week after administration and keep them in RNA*later* (*see* **Note** **14**). 

   <span style=color:blue>注射后3天或1周，通过颈椎脱位法处死小鼠，收集肝组织并将其保存在RNA*later*中（参见**注释** **14**）。</span>

3. Homogenize the tissues and extract the total RNAs according to the same protocol with that of the cultured cells. 

   <span style=color:blue>将组织均质化，并按照与培养细胞相同的协议提取总RNA。</span>

4. Prepare cDNAs and quantify the expression levels of the target gene by real-time qPCR (*see* **Note** **12**). 

   <span style=color:blue>制备cDNA，并通过实时qPCR定量目标基因的表达水平（参见**注释** **12**）。</span>

5. Administer multiple doses of GalNAc-siRNA to achieve potent and durable gene silence and treatment effect. Examples of gene silence performances with single or multiple doses of GalNAc-siRNA are shown in Fig. 6. 

   <span style=color:blue>多次给药GalNAc-siRNA，以实现强效和持久的基因沉默和治疗效果。单次或多次给药GalNAc-siRNA的基因沉默性能示例如图6所示。</span>

6. As an optional choice, quantify siRNAs exposed in liver tissue and load into the RISC by stem-loop reverse transcription followed by Taqman PCR (Fig. 7c, d). 

   <span style=color:blue>作为一个可选方案，通过茎环逆转录后接Taqman PCR定量肝组织中暴露的siRNA并加载到RISC中（图7c、d）。</span>


![485053_1_En_6_Fig6_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_6_Fig6_HTML.png)

<span style=font-family:kaiti;text-align:center>**Fig. 6** Gene silencing by GalNAc-siRNA conjugate targeting mouse transthyretin (mTTR) in C57BL/6 mice. (**a**) mRNA expression of mTTR in liver tissues after treated with single dose of GalNAc-siRNA conjugate (dark blue; 0.2, 1, and 5 mg/kg, *n* = 5). (**b**) Long-term reduction of TTR protein in mice during weekly subcutaneous dosing at 1 mg/kg. The TTR protein was analyzed with serum samples by ELISA (enzyme-linked immunosorbent assay). Data were shown as mean ± standard error. (The figure is adapted and modified from the literature. Copyright © 2014 American Chemical Society)</span>

![485053_1_En_6_Fig7_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_6_Fig7_HTML.png)

**Fig. 7** The in vivo performances of GNA-modified GalNAc-siRNA conjugate targeting hydroxyacid oxidase 1 (HAO1). (**a**) The modification design of siRNA. (**b**) Off-target effect evaluated by RNA-seq in rat hepatocytes. (**c**, **d**) siRNA amount in liver tissue (**c**) and RISC (**d**) that quantified by stem-loop RT-qPCR. (**e**) Glutamate dehydrogenase (GLDH) levels measured with rat serum specimen. (**f**) H&E staining of the liver tissues collected at necropsy. Error bars represent standard deviation of the mean. **p* < 0.05. (The figure is adopted from the literature, Copyright 2018 Nature Publishing Group)

### 3.6 In Vivo Toxicity of GalNAc-siRNA Conjugate

1. According to the guidelines of toxicity assessment , a series of studies need to be performed for Investigational New Drug (IND) application. These assessments include but not limited to acute toxicity test, long-term toxicity test, genetic toxicity test, reproductive toxicity test, and carcinogenic toxicity test. Herein, we mainly discuss some preliminary toxicity assessments. 

2. Subcutaneously administer GalNAc-siRNA conjugate to toxicology-relevant animal species, such as rat and nonhuman primate (NHP), at toxicological doses (*see* **Notes** **15** and **16**). 

3. Collect plasma or serum samples at 3–6 h or 24 h after administration. 

4. Examine the cytokines, such as TNF-α, IFN-γ, IL-1β, IL-2, IL-5, IL-6, IL-12(p70), MCP-1, KC, GM-CSF using Luminex® assays (high-throughput multiplex bead-based assays) with Luminex 100 system or ELISA. 

5. Count the blood cell with whole blood samples to analyze the profiles of the key components in the blood, such as red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. 

6. In another study, do not collect any sample within 2 weeks after siRNA injection. Instead, perform clinical observations for 2 weeks. In this case, record clinical symptoms, including animal appearance, eating, drinking, excretion, behavior, and response to stimulation during this process. Finally, as an optional choice, collect the blood samples, measure parameters revealing the liver and kidney functions (e.g., aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), glutamate dehydrogenase (GLDH), serum creatinine (CREA), blood urea nitrogen (BUN)), and analyze cytokines and the blood cells. Evaluate the pathological changes of the tissue samples. 

7. An example of toxicity evaluation of GalNAc-siRNA conjugate is shown in Fig. [7e, f](clbr://internal.invalid/OEBPS/html/485053_1_En_6_Chapter.xhtml#Fig7). It has been demonstrated that GNA positioned at 7′ of siRNA guide strand can significantly erase the seed region-mediated off-target effect and therefore dramatically alleviate the hepatotoxicity. 


## 4 Notes

1. Use other alignment tools. 

2. Some commonly used online siRNA design tools are shown as follows:

   (a) siDESIGN Center https://horizondiscovery.com/products/tools/siDESIGN-Center.

   (b) siDirect 2.0 (http://sidirect2.rnai.jp/).

   (c) Block-iT RNAi Designer (https://rnaidesigner.invitrogen.com/rnaiexpress/setOption.do?designOption=sirna).

   (d) DSIR (http://www.bioinfo.ensmp.fr/dsir/).

   (e) GenScript siRNA Target Finder (https://www.genscript.com/tools/sirna-target-finder).

   (f) RNAi Design Tool (https://sg.idtdna.com/site/order/designtool/index/DSIRNA_CUSTOM).

   (g) siDRM (http://c1.accurascience.com/siDRM/index.php).

   (h) siRNA Selection Server (http://jura.wi.mit.edu/bioc/siRNAext/).

   (i) OptiRNA (http://optirna.unl.edu/). 

3. Alternatively, design siRNAs separately with the transcripts for targeting conserved regions across species. Combine siRNA lists reported by different tools, and analyze their sequence features to determine if there is any siRNA targeting the conserved regions.

4. Combine the siRNA sequences and verify if there is any siRNA that is reported by more than one tool when using multiple tools to design siRNA. Prefer siRNA(s) reported by more than one tool, especially if the algorithms are different from each other.

5. Typically, select less than ten siRNAs for further activity evaluation for basic research because higher than 80% silencing efficiency usually can be achieved within these siRNAs. There is no necessity to consider the intellectual property issues if we do not intend to submit a patent application. Otherwise, select dozens or even thousands of siRNAs for screening and evaluation.

6. Alternatively, chemically modified siRNA. Perform the following tests with the modified siRNAs. The advantage of using modified siRNA is saving time and cost. However, a potential risk is that we may miss some siRNAs with high activity when they are not modified. Because chemical modification may influence the activity although the modification chemistry is rationally designed and optimized.

7. If the library of siRNAs is not large, for instance, less than 20 siRNAs, directly use RT-qPCR for activity evaluation instead of using luciferase reporter system.

8. Evaluate the activity of siRNA with psiCheck reporter vector, because it is demonstrated that there is no significant difference between the siRNAs targeting the CDS region and those targeting the 3′-UTR, regarding to their silencing activities, as evaluated by reporter system [[9](clbr://internal.invalid/OEBPS/html/485053_1_En_6_Chapter.xhtml#CR9)]. 

9. Use other nucleic acid transfection reagents, e.g., Lipofectamine 3000 and Lipofectamine RNAiMAX. 

10. Typically, use a scrambled siRNA in both luciferase assay and PCR assays, and normalize the activity of tested siRNA to that of the scrambled siRNA. However, if the Ct values of untreated sample, mock sample, and scrambled siRNA-treated sample are consistent, use all the above negative controls for normalization. 

11. The sequence of a scrambled siRNA that is widely used: sense strand: UUCUCCGAACGUGUCACGUdTdT, antisense strand: ACGUGACACGUUCGGAGAAdTdT. Bioinformatics analysis shows that this siRNA target no transcript for human, mouse, rat, and monkey.

12. Determine the protein expression level with Western Blotting. In this case, extract total protein and perform the assay according to the well-established standard protocols.

13. Change the dosage according to requirements of the assay. If the activity of the tested siRNA is extremely high, use low dose. If the duration of single dose of siRNA is intended to be observed, use relatively higher dose. 

14. If the duration of siRNA potency is intended to be evaluated, choose longer period, e.g., 1 month, even half year. 

15. Determine the toxicological doses that are normally higher than the treatment doses by using dose range finding (DRF) study. 

16. Currently, siRNA therapeutics are managed as chemical drugs around the world and prefer toxicology study in NHP. Meanwhile, recommend safety evaluations in mice or rats.